Φορτώνει......
miR-579-3p controls melanoma progression and resistance to target therapy
Therapy of melanoma patients harboring activating mutations in the BRAF (V-raf murine sarcoma viral oncogene homolog B1) oncogene with a combination of BRAF and MEK inhibitors is plagued by the development of drug resistance. Mutational events, as well as adaptive mechanisms, contribute to the devel...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Proc Natl Acad Sci U S A |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
National Academy of Sciences
2016
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5003278/ https://ncbi.nlm.nih.gov/pubmed/27503895 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1607753113 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|